Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat in Anemia with Lower Risk MDS
NCT03303066Phase 3Completed
- Sponsor
- FibroGen
- Start
- Jun 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of roxadustat in anemia (3 arms), sponsored by FibroGen. Primary endpoint: Percentage of Participants With a Hemoglobin (Hb) Response to FG-4592 Without Transfusion at 26 weeks. Started Jun 2018; status: completed.
02
Drugs
roxadustat
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03303066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303066.